Figure 3.

Possible targets for DDR inhibitors (repair proteins in blue and checkpoint kinases in grey) in CRC chemotherapy with supporting evidence in cancer cell lines and animal models, or candidates “to be tested” (in red), with estimated sensitivity based on results obtained in cells with deficiency of the respective target. HRD—homologous recombination deficiency, IR—ionizing radiation, Topoi—topoisomerase inhibitor, MMS—microsatellite stable, MSI—microsatellite instable, RS—replication stress, dATR-Chk1—deficient ATR-Chk1 signaling, FOLFIRI—folinic acid/fluorouracil/irinotecan chemotherapy regimen.